S C Muluk1, A T Hirsch, E C Taffe. 1. Temple University School of Medicine, Allegheny General Hospital, Pittsburgh, PA, USA. Electronic address: muluk@usa.net.
Abstract
OBJECTIVES: Examine the effectiveness of an advanced pneumatic compression device (APCD) in reducing limb volume (LV), and to evaluate clinician and patient-reported outcomes. DESIGN: Device registry study. MATERIALS AND METHODS: Data were collected prospectively for 196 lower extremity lymphedema patients prescribed an APCD. Baseline and post-treatment LVs were calculated and clinical outcomes (skin changes, pain, and function) were assessed. Patient-reported outcomes and satisfaction utilizing a pre- and post-treatment survey were also evaluated. RESULTS: 90% of APCD-treated patients experienced a significant reduction in LV with 35% enjoying a reduction >10%. Mean LV reduction was 1,150 mL or 8% (p < .0001). Greater baseline LV and BMI were strong predictors of LV reduction (p < .0001). Clinician assessment indicated that the majority of patients experienced improvement in skin fibrosis and function. Patient-reported outcomes showed a significant increase in ability to control lymphedema through APCD treatment, with an increase in function and a reduction in the interference of pain. 66% were "very satisfied" with the APCD treatment. CONCLUSION: APCD use is associated with consistent reductions in LV, with favorable patient-reported outcomes. Results demonstrate that reduction in LV and pain, combined with functional improvement and patient satisfaction can be achieved, providing tangible benefit for lower extremity patients.
OBJECTIVES: Examine the effectiveness of an advanced pneumatic compression device (APCD) in reducing limb volume (LV), and to evaluate clinician and patient-reported outcomes. DESIGN: Device registry study. MATERIALS AND METHODS: Data were collected prospectively for 196 lower extremity lymphedemapatients prescribed an APCD. Baseline and post-treatment LVs were calculated and clinical outcomes (skin changes, pain, and function) were assessed. Patient-reported outcomes and satisfaction utilizing a pre- and post-treatment survey were also evaluated. RESULTS: 90% of APCD-treated patients experienced a significant reduction in LV with 35% enjoying a reduction >10%. Mean LV reduction was 1,150 mL or 8% (p < .0001). Greater baseline LV and BMI were strong predictors of LV reduction (p < .0001). Clinician assessment indicated that the majority of patients experienced improvement in skin fibrosis and function. Patient-reported outcomes showed a significant increase in ability to control lymphedema through APCD treatment, with an increase in function and a reduction in the interference of pain. 66% were "very satisfied" with the APCD treatment. CONCLUSION:APCD use is associated with consistent reductions in LV, with favorable patient-reported outcomes. Results demonstrate that reduction in LV and pain, combined with functional improvement and patient satisfaction can be achieved, providing tangible benefit for lower extremity patients.
Authors: C Schwahn-Schreiber; F X Breu; E Rabe; I Buschmann; W Döller; G R Lulay; A Miller; E Valesky; S Reich-Schupke Journal: Hautarzt Date: 2018-08 Impact factor: 0.751
Authors: Cody T Haun; Michael D Roberts; Matthew A Romero; Shelby C Osburn; James C Healy; Angelique N Moore; Christopher B Mobley; Paul A Roberson; Wesley C Kephart; Petey W Mumford; Michael D Goodlett; David D Pascoe; Jeffrey S Martin Journal: Eur J Appl Physiol Date: 2017-10-26 Impact factor: 3.078
Authors: Kimberly M Brayton; Alan T Hirsch; Patricia J O Brien; Andrea Cheville; Pinar Karaca-Mandic; Stanley G Rockson Journal: PLoS One Date: 2014-12-03 Impact factor: 3.240
Authors: Devarati Mitra; Paul J Catalano; Nicole Cimbak; Antonio L Damato; Michael G Muto; Akila N Viswanathan Journal: J Gynecol Oncol Date: 2015-10-08 Impact factor: 4.401